<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221805">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195845</url>
  </required_header>
  <id_info>
    <org_study_id>GAL-USA-T102</org_study_id>
    <nct_id>NCT00195845</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder</brief_title>
  <official_title>A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if galantamine augmentaion improves cognition in
      euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of
      functioning and psychopathology will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study length is 12 to 24 weeks depending on whether patients enter the crossover. Study
      also involves 3 neuropsychology testings. Reimbursement is $20 a visit and $50 each testing.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2003</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Function</measure>
  </primary_outcome>
  <enrollment>30</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60; DSM-IV diagnosis of bipolar disorder, any subtype; Baseline Mini Mental
             Status exam above 20; MRS &lt; 16; MADRS &lt; 16

        Exclusion Criteria:

          -  Current substance dependence; serious unstable medical conditions; active suicidal
             ideation; current DSM-IV for a major mood episodes; history of COPD, epilepsy,
             cardiac arrhythmia, and peptic ulcer disease; meet DSM-IV criteria for dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert T Dunn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Health Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <lastchanged_date>March 28, 2006</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
